Platelet refractoriness is defined as a poor response (no increase in the post transfusion platelet increment) following a platelet transfusion. The cause of refractoriness may be immune or non-immune in nature. Both HLA and HPA antibodies have been implicated in patients' lack of response to platelet transfusions. Investigation may include HLA and HPA antibody testing as well as HLA and HPA genotyping of the patient.
Specimen(s): Initial Screen: Five (5) full 5-7 ml EDTA (lavender) tubes mixed thoroughly by gentle agitation and one (1) 10mL SST serum tube inverted 5-10 times to activate clotting. Rescreens: One (1) 10mL SST serum tube inverted 5-10 times to activate clotting. Pediatric Patients: Contact the National Platelet Immunology Reference Laboratory (NPIRL) for minimum sample requirements.
Label specimen(s) with the required minimum information: patient’s last name, first name, PHN/ (PHIN) or hospital number or other unique identifier, date of collection and facility name.
Complete Requisition (must include):
Patient's last name, first name, date of birth and PHN/(PHIN) or hospital number or other unique identifier
Physician/Health Care Provider name
Phlebotomist name, classification, initial
Date/time of collection
Name, facility, address, contact number of individual to whom the report will be sent